Pfizer’s Newly Approved Once-Daily Xeljanz XR Is Unlikely To Expand Overall Brand Use According To The Latest Rheumatology Report From Spherix Global Insights

ZUG, Switzerland, April 20, 2016 /PRNewswire/ — A recent survey conducted by Spherix Global Insights with U.S. rheumatologists (n=96) in February indicates that despite increased dosing options for Pfizer’s Xeljanz, most physicians do not anticipate their overall use of the JAK… http://www.prnewswire.com/news-releases/pfizers-newly-approved-once-daily-xeljanz-xr-is-unlikely-to-expand-overall-brand-use-according-to-the-latest-rheumatology-report-from-spherix-global-insights-300254297.html